Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial
Thomas L Holland(Duke University), Robert C. Hyzy, Lavannya M. Pandit, Leire Balerdi-Sarasola, Robert Gottlieb, Evan Cassity, Sergio España-Cueto, Lindsay Leither, Eleftherios Mylonakis(Rhode Island Hospital), Sanjay Bhagani, D. Clark Files, Ralph Rogers, Nicole Engen(Fairview Health Services), Marisa Di Natale, Adit A. Ginde(University of Colorado Denver), Andrew M. Vekstein, Barbara W. Trautner, Peter E. Morris, Eduardo Fernández‐Cruz, Lourdes Mateu, Jonathan D. Casey, Kami Kim, Mezgebe Berhe, Beatrice Jones, R. Duncan Hite, Michael A. Matthay(University of California, San Francisco), Kathryn A. Hibbert(Duke University), Katherine L. Boyle(British Heart Foundation), Uriel Sandkovsky, Noel Ivey, Huldrych F. Günthard(University of California San Diego), Michael R. Filbin(Broad Institute), Barbine Tchamba Agbor Agbor, Angela J. Rogers, Mamta K. Jain(The University of Texas Southwestern Medical Center), Ahmad Mourad, David J. Douin, Rubria Marines‐Price, Kirk U. Knowlton, Fadi Shehadeh, Wonder Drake, Roger Paredes(Universitat Autònoma de Barcelona), Peter Chen(Cedars-Sinai Medical Center), Konstantinos N. Syrigos(National and Kapodistrian University of Athens), Eyad Almasri, Gemma Lladós, Thanh Tran, Thomas A. Murray(University of Minnesota), Greg Grandits, Garyphallia Poulakou
Cited by 127
Related Papers
Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management
|Clinical Microbiology Reviews|2015|5.1k
Recovery of Replication-Competent HIV Despite Prolonged Suppression of Plasma Viremia
|Science|1997|2.2k
Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research
|Nature Reviews Microbiology|2019|2k
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
|New England Journal of Medicine|2020|1.4k